TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Business Wire•02/11/2026•06:00 ET
0
Key Highlights
- ➤TriGemX Bio and TCGX confidentially submit draft Form S-4 to SEC
- ➤Proposed combination targets first-quarter 2027 closing, subject to approvals
- ➤Combined company expected to list on Nasdaq under ticker TGEM
- ➤Elismetrep is in Phase 3 migraine trials, with initial results expected mid-2027
- ➤Transaction requires TCGX shareholder, SEC, Nasdaq and other approvals
TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX) (“TCGX”), a publicly listed special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the “Registration Statement”) to the U.S. Securities and Exchange Commission (“SEC”).
Get started
Create a free account to read the full story.